Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ceftazidime

FDA-approved product (injectable, injection), marketed as Ceftazidime, Ceftazidime In Dextrose Container, Ceptaz and 7 more.

Registered studies
50+
Lab records
324
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ceftazidime
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection
  • Parametritis
  • Peritonitis
  • Pneumonia
  • Pyelonephritis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Third-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DD02

Repurposing investigation

Ceftazidime is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA94.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae60.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis53.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 5 of 5 lab records
  • E. coli: measured active in 41 of 47 lab records
  • K. pneumoniae: measured active in 111 of 272 lab records
Open Ceftazidime in ChEMBL Registered studies below
Show the latest 150 of 324 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ceftazidime with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation

    NCT07759453 · start 2026-10-01

    Registered record
    Registry ID
    NCT07759453
    Conditions
    Liver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization
    Interventions
    Ceftazidime - Avibactam ( CAZ-AVI); Meropenem-Vaborbactam; Imipenem+Relebactam; Cefiderocol; Aztreonam; Eravacycline; Aztreonam-Avibactam; Amoxi Clavulanate; Piperacillin + Tazobactam; Tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10-01
    Completion
    2029-09-30
    Enrolment
    168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization
    InterventionCeftazidime - Avibactam ( CAZ-AVI); Meropenem-Vaborbactam; Imipenem+Relebactam; Cefiderocol +6 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

    NCT07431307 · start 2026-07

    Registered record
    Registry ID
    NCT07431307
    Conditions
    Ventilator Associated Bacterial Pneumonia (VABP); Hospital Acquired Bacterial Pneumonia (HABP); Blood Stream Infection; Meningitis, Bacterial; Ventriculitis, Infectious
    Interventions
    BV100 with 50 mg polymyxin B plus ceftazidime/avibactam; BV100 with 50 mg polymyxin B plus cefiderocol; Best Available Therapy (BAT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-07
    Completion
    2028-07
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Bacterial Pneumonia (VABP); Hospital Acquired Bacterial Pneumonia (HABP); Blood Stream Infection; Meningitis, Bacterial +1 more
    InterventionBV100 with 50 mg polymyxin B plus ceftazidime/avibactam; BV100 with 50 mg polymyxin B plus cefiderocol; Best Available Therapy (BAT)
    PhasePhase 2
    Registry statusNot yet recruiting

  • Cefotetan Therapy for Escherichia Coli Infections

    NCT07318584 · start 2026-03

    Registered record
    Registry ID
    NCT07318584
    Conditions
    E Coli Infection; ESBL Producing E.Coli
    Interventions
    Cefotetan; Carbapenems; Beta Lactam Antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2028-08
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionE Coli Infection; ESBL Producing E.Coli
    InterventionCefotetan; Carbapenems; Beta Lactam Antibiotics
    PhasePhase 2
    Registry statusNot yet recruiting

  • Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales

    NCT07160569 · start 2025-09-01

    Registered record
    Registry ID
    NCT07160569
    Conditions
    Carbapenem-Resistant Enterobacteriaceae Infection
    Interventions
    Whole Genome Sequencing (WGS), Sequence Type Analysis (ST)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-09-01
    Completion
    2026-08-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-Resistant Enterobacteriaceae Infection
    InterventionWhole Genome Sequencing (WGS), Sequence Type Analysis (ST)
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

    NCT06406114 · start 2025-05-05

    Registered record
    Registry ID
    NCT06406114
    Conditions
    Drug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy; Beta Lactam Adverse Reaction; Drug-Induced Anaphylaxis; Cephalosporin Reaction
    Interventions
    Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge; Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge; Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge; Amoxicillin double-blind placebo-controlled drug challenge
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-05
    Completion
    2028-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy +3 more
    InterventionBeta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge; Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge; Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge +1 more
    PhasePhase 2
    Registry statusRecruiting

  • CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients

    NCT06811727 · start 2025-05-01

    Registered record
    Registry ID
    NCT06811727
    Conditions
    Severe Infection
    Interventions
    Continuos ceftazidime/avibactam infusion; Intermitent dosing as per SMPC
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-05-01
    Completion
    2027-08-01
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Infection
    InterventionContinuos ceftazidime/avibactam infusion; Intermitent dosing as per SMPC
    PhasePhase 4
    Registry statusNot yet recruiting

  • Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis

    NCT06368804 · start 2024-09-15

    Registered record
    Registry ID
    NCT06368804
    Conditions
    Bronchiectasis
    Interventions
    Antibiotic monotherapy treatment and follow-up; Antibiotic bitherapy treatment and follow-up
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-09-15
    Completion
    2028-09-15
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchiectasis
    InterventionAntibiotic monotherapy treatment and follow-up; Antibiotic bitherapy treatment and follow-up
    PhasePhase 2
    Registry statusRecruiting

  • Relationship Between Different Administration Regimens of Ceftazidime/Avibactam and Clinical Outcomes

    NCT06528028 · start 2024-07-01

    Registered record
    Registry ID
    NCT06528028
    Conditions
    Anti-Infective Agent
    Interventions
    CAZ/AVI; CAZ/AVI
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-07-01
    Completion
    2025-07-30
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnti-Infective Agent
    InterventionCAZ/AVI; CAZ/AVI
    PhasePhase 4
    Registry statusUnknown

  • Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies

    NCT05850871 · start 2023-01-06

    Registered record
    Registry ID
    NCT05850871
    Conditions
    Carbapenem-Resistant Enterobacteriaceae Infection
    Interventions
    CAZ/AVI plus Aztreonam; Conventional treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-01-06
    Completion
    2025-01-31
    Enrolment
    427

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-Resistant Enterobacteriaceae Infection
    InterventionCAZ/AVI plus Aztreonam; Conventional treatment
    PhaseNot applicable
    Registry statusUnknown

  • Nosocomial Infections in ECMO Patients

    NCT05566665 · start 2023-01-01

    Registered record
    Registry ID
    NCT05566665
    Conditions
    Acute Respiratory Distress Syndrome; Nosocomial Infection; Extracorporeal Membrane Oxygenation Complication
    Interventions
    Collection of blood and bronchoalveolar samples to study Pharmacokinetics of ceftazidime/avibactam, meropenem/varbobactam, ceftolozane/tazobactam, or cefiderocol
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2023-01-01
    Completion
    2026-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Respiratory Distress Syndrome; Nosocomial Infection; Extracorporeal Membrane Oxygenation Complication
    InterventionCollection of blood and bronchoalveolar samples to study Pharmacokinetics of ceftazidime/avibactam, meropenem/varbobactam, ceftolozane/tazobactam, or cefiderocol
    PhaseNot recorded
    Registry statusActive not recruiting

  • PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection

    NCT04961580 · start 2022-10-01

    Registered record
    Registry ID
    NCT04961580
    Conditions
    Sepsis; Antibiotic Reaction
    Interventions
    Ceftazidime Avitbatan Sodium
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-10-01
    Completion
    2026-12-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis; Antibiotic Reaction
    InterventionCeftazidime Avitbatan Sodium
    PhaseNot recorded
    Registry statusRecruiting

  • The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study

    NCT05655689 · start 2021-12-31

    Registered record
    Registry ID
    NCT05655689
    Conditions
    Bacterial Keratitis; Fungal Keratitis; Mixed Bacterial and Fungal Keratitis; Microbial Keratitis
    Interventions
    Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution; Ceftazidime 5% + vancomycin 5%; Gentamicin 1.4% + vancomycin 5%; Natamycin 5% Oph Susp; Voriconazole 1%; Natamycin 5% + voriconazole 1%; Natamycin 5%+ ceftazidime 5% + vancomycin 5%; Voriconazole 1% + ceftazidime 5% + vancomycin 5%
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-12-31
    Completion
    2023-01-01
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Keratitis; Fungal Keratitis; Mixed Bacterial and Fungal Keratitis; Microbial Keratitis
    InterventionMoxifloxacin Ophthalmic 0.5% Ophthalmic Solution; Ceftazidime 5% + vancomycin 5%; Gentamicin 1.4% + vancomycin 5%; Natamycin 5% Oph Susp +4 more
    PhaseNot recorded
    Registry statusCompleted

  • Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia

    NCT04948463 · start 2021-11-15

    Registered record
    Registry ID
    NCT04948463
    Conditions
    Febrile Neutropenia
    Interventions
    Piperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection; Amikacin Injection; Ciprofloxacin; Piperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection; Amikacin Injection; Ciprofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-11-15
    Completion
    2025-12-17
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    InterventionPiperacillin and Tazobactam for Injection; Cefepime Injection; Ceftazidime Injection; Vancomycin Injection +8 more
    PhasePhase 4
    Registry statusCompleted

  • Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection

    NCT04927312 · start 2021-10-01

    Registered record
    Registry ID
    NCT04927312
    Conditions
    Complicated Intra-abdominal Infection
    Interventions
    PF-06947386; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-10-01
    Completion
    2022-09-15
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Intra-abdominal Infection
    InterventionPF-06947386; Metronidazole
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

    NCT04882085 · start 2021-08-26

    Registered record
    Registry ID
    NCT04882085
    Conditions
    Urinary Tract Infection; Acute Pyelonephritis; Hospital Acquired Pneumonia; Ventilator-associated Pneumonia; Bacteremia; Intra-abdominal Infection
    Interventions
    Zavicefta, Ceftazidime-Avibactam; Best Available Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-08-26
    Completion
    2023-08-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection; Acute Pyelonephritis; Hospital Acquired Pneumonia; Ventilator-associated Pneumonia +2 more
    InterventionZavicefta, Ceftazidime-Avibactam; Best Available Treatment
    PhasePhase 4
    Registry statusCompleted